R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Radiotherapeutics have tremendous potential, but only a few therapies in market. But the technology is getting closer to its breakthrough moment.

R&D

A look forward to trends to come in 2026, including AI-driven drug development, advanced modalities, and cardiometabolic disease therapies.

R&D

At the Sachs Neuroscience Forum just before the start of JPM 2026 in San Francisco, pharmaphorum spoke with Amit Etkin, CEO of Alto Neuroscience.

R&D

The complexity of working with the patient population in obesity continues to challenge traditional trial design. hVIVO looks to the year ahead.

R&D

Find out more about optimising sponsor/CRO collaboration in an interview on a case study in FI cell therapy.

R&D

Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.